mAbs

Article	Citations
In silico prediction of post-translational modifications in therapeutic antibodies	288
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries	210
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	112
Correction	89
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	82
Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae	81
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	68
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	62
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	59
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	58
An antibody developability triaging pipeline exploiting protein language models	55
Correction	52
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	47
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	41
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	41
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	37
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	37
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	37
Impact of IgG subclass on monoclonal antibody developability	36
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	35
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies	33
Antibodies to watch in 2024	33
Predicting antibody binders and generating synthetic antibodies using deep learning	33
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains	31
Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability	30

The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	29
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	28
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	28
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	27
Correction	26
Structural and functional characterization of a monoclonal antibody blocking TIGIT	26
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	25
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	25
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production	24
GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	24
Quantifying antibody binding: techniques and therapeutic implications	23
Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment	23
Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applications	22
Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing	21
Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19	21
T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice	21
Epitope mapping of anti-drug antibodies to a clinical candidate bispecific antibody	21
Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan	20
Bivalent non-human gal-α1-3-gal glycan epitopes in the Fc region of a monoclonal antibody model can be recognized by anti-Gal-α1-3-Gal IgE antibodies	20
Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG 1 antibody	20
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies	20
The eIg technology to generate Ig-like bispecific antibodies	19
Comprehensive characterization of higher order structure changes in methionine oxidized monoclonal antibodies via NMR chemometric analysis and biophysical approaches	18
Rapid affinity-based purification of multi-specific antibodies using Kappa Select and Protein L	18
In silico proof of principle of machine learning-based antibody design at unconstrained scale	17
Cost and supply considerations for antibody therapeutics	16
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties	15
Evolution of phage display libraries for therapeutic antibody discovery	15
Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge	15
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier	15
Electrostatic properties of human germlines and biodistribution of small biologics	15
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations	14
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics	14
IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation	14
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework	14
Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue	14
A versatile design platform for glycoengineering therapeutic antibodies	14
A glyco-engineering approach for site-specific conjugation to Fab glycans	14
Antigenic landscapes on Staphylococcus aureus pore-forming toxins reveal insights into specificity and cross-neutralization	14
Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains	13
Engineering death resistance in CHO cells for improved perfusion culture	13
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG 1 antibodies	13
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	13
Leveraging multi-modal feature learning for predictions of antibody viscosity	13
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	13
Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows	12
Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach	12
Reduction of monoclonal antibody viscosity using interpretable machine learning	12
Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function	12
Predicting purification process fit of monoclonal antibodies using machine learning	12

Efficient production of bispecific antibody by FAST-Ig TM and its application to NXT007 for the treatment of hemophilia A	12
International nonproprietary names for monoclonal antibodies: an evolving nomenclature system	11
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?	11
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process	11
Coactivation of Tie2 and Wnt signaling using an antibody–R-spondin fusion potentiates therapeutic angiogenesis and vessel stabilization in hindlimb ischemia	11
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays	11
Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry	11
A machine learning strategy for the identification of key in silico descriptors and prediction models for IgG monoclonal antibody developability properties	11
Antibody markup language (AbML) — a notation language for antibody-based drug formats and software for creating and rendering AbML (abYdraw)	10
A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects	10
Discovery and characterization of a monoclonal antibody targeting a conformational epitope of IL-6/IL-6Rα to inhibit IL-6/ IL-6Rα /gp130 hexameric signaling complex formation	10
Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation	10
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1	10
Illuminating a biologics development challenge: systematic characterization of CHO cell-derived hydrolases identified in monoclonal antibody formulations	9
NAb-seq: an accurate, rapid, and cost-effective method for antibody long-read sequencing in hybridoma cell lines and single B cells	9
Development of QSAR models for in silico screening of antibody solubility	9
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors	9
Determination of ultra-trace metal-protein interactions in co-formulated monoclonal antibody drug product by SEC-ICP-MS	9
The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity	9
Understanding the structure–property relationship of bispecific monoclonal antibodies with Fc site-specific substitutions	9
Upstream cell culture process characterization and in-process control strategy development at pandemic speed	9
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers	9
Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows	8
Prediction of protein biophysical traits from limited data: a case study on nanobody thermostability through NanoMelt	8
Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties	8
Identification and characterization of an unexpected isomerization motif in CDRH2 that affects antibody activity	8
Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy	8
Correction	8
An adapted consensus protein design strategy for identifying globally optimal biotherapeutics	8
A library approach for the de novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization	8
High-throughput profiling of antibody self-association in multiple formulation conditions by PEG stabilized self-interaction nanoparticle spectroscopy	7
IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine releas	7
BERT2DAb: a pre-trained model for antibody representation based on amino acid sequences and 2D-structure	7
Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age	7
Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies	7
Affinity-controlled capture and release of engineered monoclonal antibodies by macroporous dextran hydrogels using coiled-coil interactions	7
BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning	7
Modulation of the high concentration viscosity of IgG 1 antibodies using clinically validated Fc mutations	7
Accelerating high-concentration monoclonal antibody development with large-scale viscosity data and ensemble deep learning	7
Early determination of potential critical quality attributes of therapeutic antibodies in developability studies through surface plasmon resonance-based relative binding activity assessment	7
Suitability of transiently expressed antibodies for clinical studies: product quality consistency at different production scales	7
Determining the affinities of high-affinity antibodies using KinExA and surface plasmon resonance	7
Computational models for studying physical instabilities in high concentration biotherapeutic formulations	7
Large-scale data mining of four billion human antibody variable regions reveals convergence between therapeutic and natural antibodies that constrains search space for biologics drug discovery	6
Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy	6
Achieving Acceleration to First-in-Human: MSD’s Learnings on Platform Method Validation Strategy	6
Proceedings of the 15 th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals	6
Molecular recognition requires dimerization of a VHH antibody	6
Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic	6
Correction	6
Analysis of how antigen mutations disrupt antibody binding interactions toward enabling rapid and reliable antibody repurposing	6
The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras	6
Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species	6
Development of T-cell engagers selective for cells co-expressing two antigens	6
FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques	6
Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions	6
Characterization of high-molecular weight by-products in the production of a trivalent bispecific 2+1 heterodimeric antibody	6
Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors	5
Interplay of heavy chain introns influences efficient transcript splicing and affects product quality of recombinant biotherapeutic antibodies from CHO cells	5
Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice	5
Recommended nomenclature convention for the NISTCHO cell line and its product monoclonal antibody, cNISTmAb	5
A novel in vitro serum stability assay for antibody therapeutics incorporating internal standards	5
A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity	5
Successful targeting of multidrug-resistant tumors with bispecific antibodies	5
Use of poxvirus display to select antibodies specific for complex membrane antigens	5
Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity	5
In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies	5
Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors	5
Fast-tracking antibody maturation using a B cell-based display system	5
Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders	5
Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition	5
Correction	5
Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer	4
A perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies	4
Design of orthogonal constant domain interfaces to aid proper heavy/light chain pairing of bispecific antibodies	4
Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain	4
Strategies for clinical dose optimization of T cell-engaging therapies in oncology	4
Mechanistic insights into the rational design of masked antibodies	4
Correlated analytical and functional evaluation of higher order structure perturbations from oxidation of NISTmAb	4
GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models	4

HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure	4
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity	4
Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice	4
Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper	4
YAbS: The Antibody Society’s antibody therapeutics database	4
Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans	4
TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life	4
Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering	4
Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET	4
Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats	4
Optimizing asymmetric antibody purification: a semi-automated process and its digital integration	4
Deciphering cross-species reactivity of LAMP-1 antibodies using deep mutational epitope mapping and AlphaFold	4
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy	4
Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors	4
How to think about designing smart antibodies in the age of genAI: integrating biology, technology, and experience	4
A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies	4
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer	4